% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Siegmund:307465,
      author       = {S. C. Siegmund and E. Novruzov and E. Mamlins and Y. Mori
                      and S. Otto and M. Canis and T. Watabe and R. P. Baum and R.
                      A. Werner$^*$ and F. L. Giesel},
      title        = {{C}urrent status of {FAP} therapy in solid tumors.},
      journal      = {Seminars in nuclear medicine},
      volume       = {nn},
      issn         = {0001-2998},
      address      = {New York, NY [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2025-03064},
      pages        = {nn},
      year         = {2025},
      note         = {epub},
      abstract     = {FAP-ligands as novel cancer radiopharmaceuticals in nuclear
                      medicine have been recently translated successfully into the
                      clinical space. Particularly small molecules (i.e. FAPI-46,
                      FAPI-74) and peptides (i.e. FAP-2286, DOTAGA.SA.FAPi) seem
                      to be some of the most promising molecular probes for
                      imaging and therapy. Back in 2019, there have been slight
                      reservations about adopting this new imaging probe, after
                      the decades of the solidly established role of FDG PET/CT in
                      oncological imaging. At that time, it was expected that
                      these novel ligands might challenge Onco-PET as new
                      cornerstones in the individualized tumor staging and even
                      beyond. However, FAP-targeted imaging is today not intended
                      to replace FDG PET/CT, but rather to complement cancer
                      imaging and therapy, where cancer subtypes exhibit low
                      glucose metabolism which often leads to moderate or very
                      insufficient FDG uptake. Recently, numerous FAP-imaging
                      studies -ranging from single-case reports to larger patient
                      cohorts and even prospective trials have reinforced the
                      empirical understanding of FAP-imaging as a potentially
                      'disruptive' modality compared to FDG PET/CT. The broader
                      application of FAPI PET/CT has gained momentum, shaping a
                      new narrative in oncological imaging and beyond. FAPI PET/CT
                      is now increasingly recognized as a novel imaging agent that
                      does not aim to replace FDG PET/CT, but rather supports it
                      by enhancing diagnostic accuracy in specific sub-cohort of
                      tumor entities, where FDG PET/CT tends to underperform.
                      Several FAP-derivates- such as FAPI-04, FAPI-46, FAPI-74 for
                      PET imaging as well as FAPI-34 for SPECT imaging were
                      rapidly introduced into clinical practice. To date,
                      FAP-imaging agents have steadily paved their way into
                      clinical practice, particularly in tumor entities such as
                      pancreatic ductal adenocarcinoma, gastroesophageal cancers,
                      and hepatocellular carcinoma. Even in lung cancer, where FDG
                      PET/CT has long held a well-established and clinically
                      robust role, FAPI PET/CT has quickly emerged as a strong
                      competitor, especially in case of lung adenocarcinoma. FAPI
                      PET/CT has been gaining increasing acceptance beyond
                      academic and scientific field as a tool for improved
                      oncological imaging, while FAP theranostics is still in the
                      elaboration and early translation. In contrast to imaging
                      probes, FAP-derivates for therapy require a rather long
                      residence (>48 h) time following successful target-binding
                      at the cancer-associated fibroblast or FAP-positive tumor
                      cells to enable the radiotoxic effect (beta- and
                      alpha-emitter) and deliver enough LET to the cancer
                      microenvironment. Meanwhile, FAP-based imaging probes are
                      advancing into the clinical application, with Phase-II/III
                      clinical trials expected as early as Q4/2025 (NCT07217704
                      $\&$ NCT07217717). In contrast, FAP-targeted therapeutics
                      remain in the Phase-I or proof-of-concept stage but brings
                      hope for patients with systemic disease who are left out and
                      urgently need additional innovation drives beyond the
                      standard care. This review article will give insight into
                      the most recent developments in the FAP-Therapeutic
                      applications of cancer treatments using several different
                      promising FAP-derivates to improve FAP-theranostic in
                      oncology.},
      subtyp        = {Review Article},
      keywords     = {(177)Lu (Other) / Cancer-associated fibroblasts (Other) /
                      FAPI (Other) / Fibroblast activation protein (Other) /
                      Radioligand therapy (Other) / Solid tumors (Other) /
                      Theranostics (Other)},
      cin          = {MU01},
      ddc          = {610},
      cid          = {I:(DE-He78)MU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41455672},
      doi          = {10.1053/j.semnuclmed.2025.11.022},
      url          = {https://inrepo02.dkfz.de/record/307465},
}